UY36347A - Compuestos y su uso como inhibidores de bace - Google Patents

Compuestos y su uso como inhibidores de bace

Info

Publication number
UY36347A
UY36347A UY0001036347A UY36347A UY36347A UY 36347 A UY36347 A UY 36347A UY 0001036347 A UY0001036347 A UY 0001036347A UY 36347 A UY36347 A UY 36347A UY 36347 A UY36347 A UY 36347A
Authority
UY
Uruguay
Prior art keywords
alzheimer
disease
compounds
present application
cognitive impairment
Prior art date
Application number
UY0001036347A
Other languages
English (en)
Inventor
Roland Bürli
Duggan Mark
Holenz Jörg
Johansson Patrik
Kolmodin Karin
Thorne Philip Vellacott
Mckenzie Michael John
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY36347A publication Critical patent/UY36347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud se refiere a compuestos de fórmula (I), (Ia) o (Ib) y sus composiciones/preparaciones farmacéuticas. La presente solicitud se refiere además a métodos para tratar o evitar patologías relacionadas con A¿ como síndrome de Down; angiopatía ¿-amiloide, como de modo no taxativo angiopatía amiloide cerebral o hemorragia cerebral hereditaria; trastornos asociados con el deterioro cognitivo como de modo no taxativo MCI ("deterioro cognitivo leve"); enfermedad de Alzheimer; pérdida de memoria; síntomas de déficit de atención asociados con enfermedad de Alzheimer; neurodegeneración asociada con enfermedades, como enfermedad de Alzheimer o demencia.
UY0001036347A 2014-10-07 2015-10-07 Compuestos y su uso como inhibidores de bace UY36347A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060752P 2014-10-07 2014-10-07

Publications (1)

Publication Number Publication Date
UY36347A true UY36347A (es) 2016-04-01

Family

ID=55652644

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036347A UY36347A (es) 2014-10-07 2015-10-07 Compuestos y su uso como inhibidores de bace

Country Status (5)

Country Link
US (1) US10053453B2 (es)
AR (1) AR102202A1 (es)
TW (1) TW201629025A (es)
UY (1) UY36347A (es)
WO (1) WO2016055858A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122268A1 (en) 2017-12-21 2019-06-27 Astrazeneca Ab Processes for the stereoselective preparation of bace inhibitors
WO2019122421A1 (en) 2017-12-22 2019-06-27 Astrazeneca Ab Stereoselective ketone reduction using a ketoreductase enzyme
WO2019129755A1 (en) 2017-12-29 2019-07-04 Astrazeneca Ab Ketal hydrogenation
WO2019129750A1 (en) 2017-12-29 2019-07-04 Astrazeneca Ab Processes for the racemization of dihydroimidazole ring systems

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064418A1 (en) 2007-11-14 2009-05-22 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
TWI464153B (zh) * 2009-03-13 2014-12-11 Vitae Pharmaceuticals Inc β－分泌酶之抑制劑
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
WO2013044092A1 (en) * 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
BR112014029597A2 (pt) * 2012-05-30 2017-11-07 Comentis Inc compostos de cromano
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt

Also Published As

Publication number Publication date
US10053453B2 (en) 2018-08-21
TW201629025A (zh) 2016-08-16
WO2016055858A1 (en) 2016-04-14
AR102202A1 (es) 2017-02-08
US20170313686A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CO2017011851A2 (es) Compuestos novedosos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES
CR20130308A (es) Compuestos y su uso como inhibidores de bace
ECSP17031525A (es) Composiciones novedosas, usos y métodos para hacerlas
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
EA201691582A1 (ru) Новые фармацевтические препараты
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
HRP20182138T1 (hr) Modificirani serpini za liječenje poremećaja s krvarenjem
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CR20170186A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CL2015002897A1 (es) Inhibidores de bace1
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
CR20170247A (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CU20170158A7 (es) Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204